Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash from Financing Activities for 7 consecutive years, with $181000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities fell 60.57% to $181000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $840000.0 through Sep 2025, down 36.27% year-over-year, with the annual reading at $1.4 million for FY2024, 93.63% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $181000.0 at Pulmonx, up from -$67000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $20.7 million in Q1 2023, with the low at -$67000.0 in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $1.6 million, with a median of $181000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities surged 10015.38% in 2022, then plummeted 204.55% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $150000.0 in 2021, then crashed by 55.33% to $67000.0 in 2022, then crashed by 74.63% to $17000.0 in 2023, then surged by 264.71% to $62000.0 in 2024, then skyrocketed by 191.94% to $181000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $181000.0, -$67000.0, and $664000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.